• Contact
  • Location
  • Sitemap
  • About
    • Company Profile
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
    • Careers
    • Contact
  • Technology
    • Immunicum’s Approach
    • Ilixadencel
    • DCP-001
    • Publications
  • Pipeline
    • Pipeline
    • Clinical Trial Information
    • Expanded Access / Compassionate Use Policy
  • Partnering
  • Investors
    • Overview
    • Press releases
      • 2021
      • 2020
      • 2019
      • 2018
      • 2017
      • 2016
      • 2015
      • 2014
      • 2013
      • Subscribe
    • Events & Presentations
    • Corporate Governance
      • Articles of Association
      • General meeting
      • Board of directors
      • Corporate governance reports
      • Senior Executives
      • Nomination Committee
      • Remuneration and the remuneration committee
      • Auditors and audit committee
      • Scientific committee
      • Scientific Advisory Board
    • Shareholder & Stock Info
      • Shareholders
      • Insider
      • Investment calculator
      • Share price look-up
    • Analyst Coverage
    • Financial Reports
    • Financial calendar
    • DCprime Merger Information
      • Overview
      • Media
    • Secured Rights issue 2018
    • Secured Rights issue 2017
    • Downloads
  • Investerare (SE)
    • Översikt
    • Pressmeddelanden
      • 2021
      • 2020
      • 2019
      • 2018
      • 2017
      • 2016
      • 2015
      • 2014
      • 2013
      • Prenumerera
    • Events & Presentationer
    • Bolagsstyrning
      • Bolagsordning
      • Bolagsstämma
      • Styrelse
      • Bolagsstyrningsrapporter
      • Ledande befattningshavare
      • Valberedning
      • Ersättningar och ersättningsutskott
      • Revisorer och revisionsutskott
      • Vetenskapligt utskott
      • Vetenskapligt råd
    • Aktien
      • Aktieägare
      • Insiders
      • Investment calculator
      • Share price look-up
    • Analys
    • Finansiella rapporter
    • Finansiell kalender
    • Garanterad nyemission 2018
    • Tidigare emissioner
      • Garanterad nyemission 2017
  • News & Events
    • Press releases
    • Immunicum in the News
    • Events
Immunicum
  • Contact
  • Location
  • Sitemap
  • About
    • Company Profile
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
    • Careers
    • Contact
  • Technology
    • Immunicum’s Approach
    • Ilixadencel
    • DCP-001
    • Publications
  • Pipeline
    • Pipeline
    • Clinical Trial Information
    • Expanded Access / Compassionate Use Policy
  • Partnering
  • Investors
    • Overview
    • Press releases
      • 2021
      • 2020
      • 2019
      • 2018
      • 2017
      • 2016
      • 2015
      • 2014
      • 2013
      • Subscribe
    • Events & Presentations
    • Corporate Governance
      • Articles of Association
      • General meeting
      • Board of directors
      • Corporate governance reports
      • Senior Executives
      • Nomination Committee
      • Remuneration and the remuneration committee
      • Auditors and audit committee
      • Scientific committee
      • Scientific Advisory Board
    • Shareholder & Stock Info
      • Shareholders
      • Insider
      • Investment calculator
      • Share price look-up
    • Analyst Coverage
    • Financial Reports
    • Financial calendar
    • DCprime Merger Information
      • Overview
      • Media
    • Secured Rights issue 2018
    • Secured Rights issue 2017
    • Downloads
  • Investerare (SE)
    • Översikt
    • Pressmeddelanden
      • 2021
      • 2020
      • 2019
      • 2018
      • 2017
      • 2016
      • 2015
      • 2014
      • 2013
      • Prenumerera
    • Events & Presentationer
    • Bolagsstyrning
      • Bolagsordning
      • Bolagsstämma
      • Styrelse
      • Bolagsstyrningsrapporter
      • Ledande befattningshavare
      • Valberedning
      • Ersättningar och ersättningsutskott
      • Revisorer och revisionsutskott
      • Vetenskapligt utskott
      • Vetenskapligt råd
    • Aktien
      • Aktieägare
      • Insiders
      • Investment calculator
      • Share price look-up
    • Analys
    • Finansiella rapporter
    • Finansiell kalender
    • Garanterad nyemission 2018
    • Tidigare emissioner
      • Garanterad nyemission 2017
  • News & Events
    • Press releases
    • Immunicum in the News
    • Events
You are here:HomeInvestorsPress ReleasesPressreleases 2015

Investors

  • Overview
  • Press releases
    • 2021
    • 2020
    • 2019
    • 2018
    • 2017
    • 2016
    • 2015
    • 2014
    • 2013
    • Subscribe
  • Events & Presentations
  • Corporate Governance
    • Articles of Association
    • General meeting
    • Board of directors
    • Corporate governance reports
    • Senior Executives
    • Nomination Committee
    • Remuneration and the remuneration committee
    • Auditors and audit committee
    • Scientific committee
    • Scientific Advisory Board
  • Shareholder & Stock Info
    • Shareholders
    • Insider
    • Investment calculator
    • Share price look-up
  • Analyst Coverage
  • Financial Reports
  • Financial calendar
  • DCprime Merger Information
    • Overview
    • Media
  • Secured Rights issue 2018
  • Secured Rights issue 2017
  • Downloads

Press releases 2015

  • All
  • Regulatory release

Immunicum has received approval to extend the phase I/II-study in liver cancer by up to six patients to be treated with INTUVAX in combination with first-line treatments

16 December 2015 Read more

Immunicum has received approval to extend the phase I/II-study in liver cancer by up to six patients to be treated with INTUVAX in combination with first-line treatments

16 December 2015 Read more

Immunicum announces that the Company has received approval to start a phase I/II study in patients with gastrointestinal stromal tumor

16 December 2015 Read more

Immunicum announces that the Company has received approval to start a phase I/II study in patients with gastrointestinal stromal tumor

16 December 2015 Read more

Immunicum reports updated data from the INTUVAX phase I/II study in liver cancer and announces plan for the continuation of the study

25 November 2015 Read more

Immunicum reports updated data from the INTUVAX phase I/II study in liver cancer and announces plan for the continuation of the study

25 November 2015 Read more

Immunicum’s patent application regarding the cancer immune primer INTUVAX will be granted in Japan

20 November 2015 Read more

Immunicum's patent application regarding the cancer immune primer INTUVAX will be granted in Japan

20 November 2015 Read more

Immunicum presents continued improvement in phase I/II survival data for INTUVAX-treated renal cancer patients

17 November 2015 Read more

Immunicum presents continued improvement in phase I/II survival data for INTUVAX-treated renal cancer patients

17 November 2015 Read more

Immunicum’s patent application regarding the cancer immune primer INTUVAX will be granted in Europe

9 November 2015 Read more

Immunicum's patent application regarding the cancer immune primer INTUVAX will be granted in Europe

9 November 2015 Read more

Immunicum prepares for listing on NASDAQ Stockholm’s main market in 2016

30 October 2015 Read more

Immunicum prepares for listing on NASDAQ Stockholm's main market in 2016

30 October 2015 Read more

IMMUNICUM AB: YEAR-END REPORT 2014/2015 (JULY-JUNE)

18 September 2015 Read more

IMMUNICUM AB: YEAR-END REPORT 2014/2015 (JULY-JUNE)

18 September 2015 Read more

Immunicum in collaboration with Karolinska Institute submits an application for starting a clinical study with INTUVAX® in GIST

17 September 2015 Read more

Immunicum in collaboration with Karolinska Institute submits an application for starting a clinical study with INTUVAX® in GIST

17 September 2015 Read more

Immunicum provides Ad5PTDf35 adenovirus technology to Rutgers Cancer Institute

7 September 2015 Read more

Immunicum provides Ad5PTDf35 adenovirus technology to Rutgers Cancer Institute

7 September 2015 Read more

Immunicum updates safety and survival data in phase I/II liver cancer study with INTUVAX

24 August 2015 Read more

Immunicum updates safety and survival data in phase I/II liver cancer study with INTUVAX

24 August 2015 Read more

Magnus Persson proposed new Board member of Immunicum

13 August 2015 Read more

Magnus Persson proposed new Board member of Immunicum

13 August 2015 Read more

Immunicum strengthens the clinical organization

5 August 2015 Read more

Immunicum strengthens the clinical organization

5 August 2015 Read more

Immunicum presents continued improvement in phase I/II survival data for INTUVAX-treated renal cancer patients

4 August 2015 Read more

Immunicum presents continued improvement in phase I/II survival data for INTUVAX-treated renal cancer patients

4 August 2015 Read more

Immunicum hires Lise-Lotte Hallbäck as new CFO

13 July 2015 Read more

Immunicum hires Lise-Lotte Hallbäck as new CFO

13 July 2015 Read more

Immunicum includes first patient in a phase II study in patients with metastatic kidney cancer

5 May 2015 Read more

Immunicum includes first patient in a phase II study in patients with metastatic kidney cancer

5 May 2015 Read more

Immunicum clarifies statement on liver cancer study

28 April 2015 Read more

Immunicum clarifies statement on liver cancer study

28 April 2015 Read more

Immunicum updates safety and survival data in liver cancer study with INTUVAX

23 April 2015 Read more

Immunicum updates safety and survival data in liver cancer study with INTUVAX

23 April 2015 Read more

Immunicum: Management sells a small amount of their shares

17 April 2015 Read more

Immunicum: Management sells a small amount of their shares

17 April 2015 Read more

Immunicum supplies NCI research with technology for CRISPR/Cas9 system

27 March 2015 Read more

Immunicum supplies NCI research with technology for CRISPR/Cas9 system

27 March 2015 Read more

Immunicum’s Chief Scientific Officer presented the technology behind the cancer vaccine INTUVAX at a symposium at Karolinska Institutet in conjunction with world-leading researchers in immunology

13 March 2015 Read more

Immunicum's Chief Scientific Officer presented the technology behind the cancer vaccine INTUVAX at a symposium at Karolinska Institutet in conjunction with world-leading researchers in immunology

13 March 2015 Read more

Immunicum receives approval to start phase II study with the therapeutic cancer vaccine INTUVAX

17 February 2015 Read more
Press releases

Choose which language you would like to receive the press release in:

Swedish English
Contact us

Östermalmstorg 5
114 42 Stockholm
Sweden

Telephone

+46 (0)8 732 8400

Email

info@immunicum.com

For information about personal data processing at Immunicum, please see Immunicum´s Integrity Policy

Social
Links
  • Sitemap
  • Integrity and Cookie Policy

© 2002-2021 Immunicum AB. All rights reserved.

Designer mkmedia
To top

We use cookies to improve the user experience on Immunicum. Read more about Cookies

Approve